Sequoia China co-leads $37.5m Series B for biotherapeutics firm HiFiBiO

HiFiBiO Therapeutics, an emerging multinational biotherapeutics company that seeks to combat diseases by mobilizing the human immune system, has raised $37.5 million in a Series B financing co-led by Sequoia China and LYFE Capital.